Physician profile
Grace A Warwick
NPI 1730833724
$3,771.10
in general payments reported to CMS, 2019-2025
25 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $589 · 2023: $1,018 · 2024: $1,093 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $842.96 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $640.63 | 2022-2025 | |
| Lilly USA, LLC | $456.55 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $430.69 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $211.97 | 2023-2025 | |
| Exact Sciences Corporation | $163.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $160.56 | 2022-2025 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $141.19 | 2022-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.87 | 2022-2024 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Glaxosmithkline, LLC. | $96.79 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.01 | 2022-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $64.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.76 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $46.94 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $33.99 | 2022-2024 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.85 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $33.08 | 2024 | |
| Seqirus USA INC | $23.30 | 2025 | Flucelvax, Fluad |
| Sanofi-Aventis U.S. LLC | $19.63 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $18.18 | 2022 | |
| Amarin Pharma, INC. | $17.78 | 2022 | |
| Tactile Systems Technology INC | $17.53 | 2024 | Entre Plus, Flexitouch Plus |
| Abiomed | $15.91 | 2024 | Impella |
| Ars Pharmaceuticals Operations, INC. | $15.44 | 2025 | Neffy |
| Boston Scientific Corporation | $14.84 | 2024 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Warwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.